BTA test

BTA test

Bladder tumour antigen test. A qualitative, point-of-care test that identifies a human complement factor H-related protein, which is produced by several human bladder cell lines but not by non-malignant epithelial cell lines. It has a claimed sensitivity comparable to that of cytology for high-grade tumours and claimed to be better than cytology for low-grade tumours.
References in periodicals archive ?
17] To understand the nuances of the BTA test and the urine cytology test in diagnosis, we conducted a systematic review of published findings and used meta-analysis techniques to quantitatively combine results.
A significant interaction was observed between exercise and medication use based on results of the BTA test and the Digit Span Forward and Backward Task.
Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
The most significant improvement was experienced by a woman who was 29 years of age chronologically, whose first BTA test showed her to be 43 biological years of age, and whose second BTA test after consumption of the tea showed her to be 27 biological years of age," says Dr.
Because original BTA test sensitivity (approximately 40%) was no better than that of cytology, several assay modifications were introduced, including the BTA stat and BTA TRAK.
He has also served as President and CEO of Bard Diagnostics (formerly Bainbridge Sciences), a pioneering cancer diagnostics company that developed and launched the BTA test, the first diagnostic test for bladder cancer approved by the U.
3,4] A number of novel immunoassays for cancer-associated proteins in voided urine have been investigated as diagnostic tool to replace cytology, including BTA test, BTA Stat test, NMP22 and Immunocyt.
After collecting samples of a patient's blood, urine and saliva, the health care practitioner performs a 10-minute BTA test resulting in a complex evaluation of the patient's cellular health.
The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder.
The new, rapid BTA stat test is even simpler to perform and improves upon the original Bard BTA Test.
Bard, will market, sell and distribute the BTA Test to the Japanese market.